|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guo Z, Wang X, Lin R, Chen L, Fan N, Chen
Y, Lin J and Yu J: Paclitaxel-based regimens as first-line
treatment in advanced gastric cancer. J Chemother. 27:94–98. 2015.
View Article : Google Scholar
|
|
3
|
Zhang D and Fan D: Multidrug resistance in
gastric cancer: Recent research advances and ongoing therapeutic
challenges. Expert Rev Anticancer Ther. 7:1369–1378. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang J, Li S, Li L, Li M, Guo C, Yao J
and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and
function. Genomics Proteomics Bioinformatics. 13:17–24. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meehan K and Vella LJ: The contribution of
tumour-derived exosomes to the hallmarks of cancer. Crit Rev Clin
Lab Sci. 53:121–131. 2016. View Article : Google Scholar
|
|
6
|
Ruivo CF, Adem B, Silva M and Melo SA: The
biology of cancer exosomes: Insights and new perspectives. Cancer
Res. 77:6480–6488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brinton LT, Sloane HS, Kester M and Kelly
KA: Formation and role of exosomes in cancer. Cell Mol Life Sci.
72:659–671. 2015. View Article : Google Scholar
|
|
8
|
Sharma A: Chemoresistance in cancer cells:
Exosomes as potential regulators of therapeutic tumor
heterogeneity. Nanomedicine (Lond). 12:2137–2148. 2017. View Article : Google Scholar
|
|
9
|
Butera G, Pacchiana R and Donadelli M:
Autocrine mechanisms of cancer chemoresistance. Semin Cell Dev
Biol. 78:3–12. 2018. View Article : Google Scholar
|
|
10
|
Sousa D, Lima RT and Vasconcelos MH:
Intercellular transfer of cancer drug resistance traits by
extracellular vesicles. Trends Mol Med. 21:595–608. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Colombo M, Raposo G and Théry C:
Biogenesis, secretion, and intercellular interactions of exosomes
and other extracellular vesicles. Annu Rev Cell Dev Biol.
30:255–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bandari SK, Purushothaman A, Ramani VC,
Brinkley GJ, Chandrashekar DS, Varambally S, Mobley JA, Zhang Y,
Brown EE, Vlodavsky I, et al: Chemotherapy induces secretion of
exosomes loaded with heparanase that degrades extracellular matrix
and impacts tumor and host cell behavior. Matrix Biol. 65:104–118.
2018. View Article : Google Scholar
|
|
13
|
Ning K, Wang T, Sun X, Zhang P, Chen Y,
Jin J and Hua D: UCH-L1-containing exosomes mediate
chemotherapeutic resistance transfer in breast cancer. J Surg
Oncol. 115:932–940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kreger BT, Johansen ER, Cerione RA and
Antonyak MA: The enrichment of survivin in exosomes from breast
cancer cells treated with paclitaxel promotes cell survival and
chemoresistance Cancers (Basel). 8. pp. 82016
|
|
15
|
Liu X, Fu Q, Du Y, Yang Y and Cho WC:
MicroRNA as regulators of cancer stem cells and chemoresistance in
colorectal cancer. Curr Cancer Drug Targets. 16:738–754. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cui SY, Wang R and Chen LB: MicroRNAs: Key
players of taxane resistance and their therapeutic potential in
human cancers. J Cell Mol Med. 17:1207–1217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhong S, Chen X, Wang D, Zhang X, Shen H,
Yang S, Lv M, Tang J and Zhao J: MicroRNA expression profiles of
drug-resistance breast cancer cells and their exosomes. Oncotarget.
7:19601–19609. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qin X, Yu S, Xu X, Shen B and Feng J:
Comparative analysis of microRNA expression profiles between A549,
A549/DDP and their respective exosomes. Oncotarget. 8:42125–42135.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X,
Shen B, Liu S, Yan D and Feng J: Cisplatin-resistant lung cancer
cell-derived exosomes increase cisplatin resistance of recipient
cells in exosomal miR-100-5p-dependent manner. Int J Nanomedicine.
12:3721–3733. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei F, Ma C, Zhou T, Dong X, Luo Q, Geng
L, Ding L, Zhang Y, Zhang L, Li N, et al: Exosomes derived from
gemcitabine-resistant cells transfer malignant phenotypic traits
via delivery of miRNA-222-3p. Mol Cancer. 16:1322017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen WX, Liu XM, Lv MM, Chen L, Zhao JH,
Zhong SL, Ji MH, Hu Q, Luo Z, Wu JZ, et al: Exosomes from
drug-resistant breast cancer cells transmit chemoresistance by a
horizontal transfer of microRNAs. PLoS One. 9:e952402014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Challagundla KB, Wise PM, Neviani P, Chava
H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, et al:
Exosome-mediated transfer of microRNAs within the tumor
microenvironment and neuroblastoma resistance to chemotherapy. J
Natl Cancer Inst. 107:1072015. View Article : Google Scholar
|
|
23
|
Patel GK, Khan MA, Bhardwaj A, Srivastava
SK, Zubair H, Patton MC, Singh S, Khushman M and Singh AP: Exosomes
confer chemoresistance to pancreatic cancer cells by promoting ROS
detoxification and miR-155-mediated suppression of key
gemcitabine-metabolising enzyme, DCK. Br J Cancer. 116:609–619.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mikamori M, Yamada D, Eguchi H, Hasegawa
S, Kishimoto T, Tomimaru Y, Asaoka T, Noda T, Wada H, Kawamoto K,
et al: MicroRNA-155 controls exosome synthesis and promotes
gemcitabine resistance in pancreatic ductal adenocarcinoma. Sci
Rep. 7:423392017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Santos JC, Lima NDS, Sarian LO, Matheu A,
Ribeiro ML and Derchain SFM: Exosome-mediated breast cancer
chemoresistance via miR-155 transfer. Sci Rep. 8:8292018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang M, Zhao C, Shi H, Zhang B, Zhang L,
Zhang X, Wang S, Wu X, Yang T, Huang F, et al: Deregulated
microRNAs in gastric cancer tissue-derived mesenchymal stem cells:
Novel biomarkers and a mechanism for gastric cancer. Br J Cancer.
110:1199–1210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Zhu M, Wang M, Yang F, Tian Y, Cai J, Yang
H, Fu H, Mao F, Zhu W, Qian H, et al: miR-155-5p inhibition
promotes the transition of bone marrow mesenchymal stem cells to
gastric cancer tissue derived MSC-like cells via NF-κB p65
activation. Oncotarget. 7:16567–16580. 2016.PubMed/NCBI
|
|
29
|
Whitehead B, Wu L, Hvam ML, Aslan H, Dong
M, Dyrskjøt L, Ostenfeld MS, Moghimi SM and Howard KA: Tumour
exosomes display differential mechanical and complement activation
properties dependent on malignant state: Implications in
endothelial leakiness. J Extracell Vesicles. 4:296852015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bockhorn J, Dalton R, Nwachukwu C, Huang
S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, et al:
MicroRNA-30c inhibits human breast tumour chemotherapy resistance
by regulating TWF1 and IL-11. Nat Commun. 4:13932013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu SJ, Yang L, Hong Q, Kuang XY, Di GH and
Shao ZM: MicroRNA-200a confers chemoresistance by antagonizing
TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 18:742018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vergara D, Tinelli A, Iannone A and Maffia
M: The impact of proteomics in the understanding of the molecular
basis of Paclitaxel-resistance in ovarian tumors. Curr Cancer Drug
Targets. 12:987–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kavallaris M: Microtubules and resistance
to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Soldevilla B, Rodríguez M, San Millán C,
García V, Fernández-Periañez R, Gil-Calderón B, Martín P,
García-Grande A, Silva J, Bonilla F, et al: Tumor-derived exosomes
are enriched in ∆Np73, which promotes oncogenic potential in
acceptor cells and correlates with patient survival. Hum Mol Genet.
23:467–478. 2014. View Article : Google Scholar
|
|
35
|
Zeng AL, Yan W, Liu YW, Wang Z, Hu Q, Nie
E, Zhou X, Li R, Wang XF, Jiang T, et al: Tumour exosomes from
cells harbouring PTPRZ1-MET fusion contribute to a malignant
phenotype and temozolomide chemoresistance in glioblastoma.
Oncogene. 36:5369–5381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang J, Yeung BZ, Cui M, Peer CJ, Lu Z,
Figg WD, Guillaume Wientjes M, Woo S and Au JL: Exosome is a
mechanism of inter-cellular drug transfer: Application of
quantitative pharmacology. J Control Release. 268:147–158. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X, Xu C, Hua Y, Sun L, Cheng K, Jia
Z, Han Y, Dong J, Cui Y and Yang Z: Exosomes play an important role
in the process of psoralen reverse multidrug resistance of breast
cancer. J Exp Clin Cancer Res. 35:1862016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bach DH, Hong JY, Park HJ and Lee SK: The
role of exosomes and miRNAs in drug-resistance of cancer cells. Int
J Cancer. 141:220–230. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao L, Liu W, Xiao J and Cao B: The role
of exosomes and ‘exosomal shuttle microRNA’ in tumorigenesis and
drug resistance. Cancer Lett. 356B:339–346. 2015. View Article : Google Scholar
|
|
40
|
Qu Y, Zhang H, Sun W, Han Y, Li S, Qu Y,
Ying G and Ba Y: MicroRNA-155 promotes gastric cancer growth and
invasion by negatively regulating transforming growth factor-β
receptor 2. Cancer Sci. 109:618–628. 2018. View Article : Google Scholar :
|
|
41
|
Bayraktar R and Van Roosbroeck K: miR-155
in cancer drug resistance and as target for miRNA-based
therapeutics. Cancer Metastasis Rev. 37:33–44. 2018. View Article : Google Scholar
|
|
42
|
Van Roosbroeck K, Fanini F, Setoyama T,
Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I,
Redis RS, D’Abundo L, et al: Combining anti-mir-155 with
chemotherapy for the treatment of lung cancers. Clin Cancer Res.
23:2891–2904. 2017. View Article : Google Scholar
|
|
43
|
Li B, Jin X, Meng H, Hu B, Zhang T, Yu J,
Chen S, Guo X, Wang W, Jiang W, et al: Morin promotes prostate
cancer cells chemosensitivity to paclitaxel through miR-155/GATA3
axis. Oncotarget. 8:47849–47860. 2017.PubMed/NCBI
|
|
44
|
Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li
Z, Wang J, Li B, Hu Y, Dong B, et al: Dual PI3K/mTOR inhibitor
BEZ235 as a promising therapeutic strategy against
paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR
pathway. Cell Death Dis. 9:1232018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar
|
|
47
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21:212016. View Article : Google Scholar
|
|
50
|
Liu F, Kong X, Lv L and Gao J: TGF-β1 acts
through miR-155 to down-regulate TP53INP1 in promoting
epithelial-mesenchymal transition and cancer stem cell phenotypes.
Cancer Lett. 359:288–298. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiang ZS, Sun YZ, Wang SM and Ruan JS:
Epithelial-mesenchymal transition: Potential regulator of ABC
transporters in tumor progression. J Cancer. 8:2319–2327. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View Article : Google Scholar : PubMed/NCBI
|
